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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract Radiofrequency ablation (RFA) is more effective for hepatocellular carcinoma
(HCC) < 3 cm. Combining percutaneous ethanol injection and RFA for HCC can increase abla-
tion; however, the long-term outcome remains unknown. The aim of this study was to compare
long-term outcomes between patients with HCC of 2e3 cm versus 3.1e4 cm and in high-risk
versus non-high-risk locations after combination therapy. The primary endpoint was overall
survival and the secondary endpoint was local tumor progression (LTP). Fifty-four consecutive
patients with 72 tumors were enrolled. Twenty-two (30.6%) tumors and 60 (83.3%) tumors were
of 3.1e4 cm and in high-risk locations, respectively. Primary technique effectiveness was com-
parable between HCC of 2e3 cm versus 3.1e4 cm (98% vs. 95.5%, pZ 0.521), and HCC in non-
high risk and high-risk locations (100% vs. 96.7%, p Z 1.000). The cumulative survival rates at
1 year, 3 years, and 5 years were 90.3%, 78.9%, and 60.3%, respectively, in patients with HCC of
2e3 cm; 95.0%, 84.4%, and 69.3% in HCC of 3.1e4.0 cm (pZ 0.397); 90.0%, 71.1%, and 71.1% in
patients with HCC in non-high-risk locations; and 92.7%, 81.6%, and 65.4% in high-risk locations
(p Z 0.979). The cumulative LTP rates at 1 year, 3 years, and 5 years were 10.2%, 32.6%, and
32.6%, respectively, in all HCCs; 12.6%, 33.9%, and 33.9% in HCC of 2e3 cm; 4.8%, 29.5%, and
29.5% in HCC of 3.1e4 cm (p Z 0.616); 16.7%, 50.0%, and 50.0% in patients with HCC in non-
high-risk locations; and 8.8%, 29.9%, and 29.9% in patients with HCC in high-risk locations
(p Z 0.283). The cumulative survival and LTP rates were not significantly different among
the various subgroups. Combining RFA and percutaneous ethanol injection achieved compara-
ble long-term outcomes in HCCs of 2e3 cm versus 3.1e4.0 cm and in high-risk versus non-high-eclare no conflicts of interest.
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Hepatocellular carcinoma (HCC) is one of the most common
malignancies and one of the major causes of mortality
worldwide [1]. Patients with early-stage HCC are candi-
dates for resection, liver transplantation, or ablation [2];
however, candidacy for resection is determined by tumor
location, size, or number of lesions, adequate liver reserve,
or comorbid conditions. Orthotopic liver transplantation is
considered for patients with poor liver function, but the
shortage of donors continues to hinder treatment.
Percutaneous radiofrequency ablation (RFA) has been
used to treat patients with HCC since 1990 and has been
widely used for > 20 years. A meta-analysis showed that
RFA achieved comparable results to liver resection in pa-
tients with HCCs 3 cm [3,4], but inferior outcomes in
patients with HCCs > 3 cm [5,6]. In addition to tumor size,
the effectiveness of RFA also depends on tumor location.
More treatment failures and complications occur after RFA
for HCCs in high-risk locations, which are close to the liver
capsule, vital organs, vessels, or central bile ducts [7].
Some studies have shown that combining RFA and
percutaneous ethanol injection (PEI) is effective for larger
HCCs, as well as HCCs in high-risk locations [8,9]. Zhang
et al. [10] have shown that combination therapy can
improve survival compared with RFA monotherapy; how-
ever, the long-term outcomes in patients with HCCs
3.1e4 cm in size and in high-risk locations after combina-
tion therapy have not been reported. The aim of this study
was to compare the long-term survival and local tumor
progression (LTP) in patients with HCCs 2e3 cm versus
3.1e4 cm in size, and in high-risk versus non-high-risk
locations.Materials and methods
Patients
This retrospective study reviewed the prospectively
collected database of consecutive patients with HCCs
4 cm in various locations after combination therapy be-
tween February 2004 and October 2011 at our institute.
Inclusion criteria were patients with larger HCCs
(3.1e4 cm) or HCCs in high-risk locations. All of the index
HCCs were diagnosed by cytological or pathological evalu-
ation, or according to the criteria of the American Associ-
ation for the Study of Liver Disease [11]. The number of
HCCs was fewer than three. All patients had cirrhosis
(ChildePugh class A or B). None of the patients had extra-
hepatic metastasis or intrahepatic vascular invasion.
Impaired coagulopathy was corrected to a safe level (pro-
thrombin time < 3 seconds and platelet count > 50  109/L) prior to treatment. All patients received combination
therapy after a comprehensive discussion in our HCC
multidisciplinary meeting. Informed consent was obtained
from all patients prior to treatment. The decision to
perform RFA alone or combine PEI and RFA was left to the
discretion of the operator. This study was approved by our
Institutional Review Board.
Definition of high-risk locations
Based on our previous description [8], high-risk location was
defined as the index tumor located within 10 mm of the
liver capsule (subcapsular location), vital organs (stomach,
duodenum, colon, gallbladder, common bile duct, or kid-
neys), the dome of the diaphragm, or directly in contact
with a vessel > 3 mm in diameter. If the tumor was located
near both structures, we chose the nearest one as the main
structure to define high-risk location. The distance be-
tween the margin of the tumor and the large vessels or
extrahepatic organs was measured on computed tomogra-
phy (CT) images (Somatom Sensation 16; Siemens, Munich,
Germany), reconstructed at 5-mm intervals. Non-high-risk
locations referred to index tumors not located in the
aforementioned high-risk locations.
Techniques of combining RFA and PEI
RFA and PEI were performed using a percutaneous approach
under real-time ultrasound (Aplio XV; Toshiba, Tokyo,
Japan). Conscious sedation with pethidine and midazolam
was achieved with vital sign monitoring during the entire
procedure. RFA and PEI were performed by one of two
hepatologists with >3 years of experience.
The RF electrode was positioned into the tumor first.
The electrode was kept 0.5e1 cm away from the vital or-
gans. PEI was performed by injection of 1e10 mL 99.5%
ethanol via a 22-gauge percutaneous needle (15e20 cm in
length). The RFA program was activated immediately after
PEI. Overlapping ablation was applied to achieve an
adequate coagulation volume to cover the entire tumor.
Follow-up protocol
All patients had follow-up for >4 months after combination
therapy. The follow-up was terminated in August 2012. The
post-treatment evaluation mainly included a-fetoprotein
and imaging studies. An abdominal echo was routinely
performed the day after combination therapy and repeated
every 3 months thereafter. At least one dynamic imaging
study (CT or magnetic resonance imaging) was performed
on all patients at 1 month and every 3 months after RFA for
assessment of complete ablation and early diagnosis of HCC
recurrence.
Table 1 Baseline characteristics of patients and tumors.
Parameters Values
Patient no. 54
Age (y) 66.3  10.3
Male sex 38 (70.3)
Viral infection
HBsAg positive 25 (46.3)
HCV antibody positive 22 (40.7)
Cirrhosis
ChildePugh A 47 (87.0)
ChildePugh B 7 (13.0)
Albumin (g/dL) 3.7  0.6
Total bilirubin (mg/dL) 1.2  0.7
Platelet count (104/mm3) 11.1  5.0
Prothrombin time (INR) 1.2  0.2
Tumor no. 72
Tumor size (cm) 2.7  0.6
2.0e3.0 cm 50 (69.4)




Ablation time (min) 21.7  12.3
Ethanol use (mL) 4.1  1.5
Data are presented as n (%) or mean  SD.
HBsAg Z hepatitis B surface antigen; HCV Z hepatitis C virus;
INR Z international normalized ratio.
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effectiveness, and LTP
Complete ablation was defined as a low attenuated area on
the dynamic liver CT scan or low signal intensity on T2-
weighted magnetic resonance imaging after the final abla-
tion therapy,which encompassed theareaof the index tumor
without nodular peripheral enhancement on dynamic studies
[6,8]. Primary technique effectiveness (PTE) was defined as
achievement of complete necrosis within three sessions of
ablation and within 3 months after the first treatment of the
indexHCC [8]. LTPwas defined as the appearance of any area
of high attenuation with peripheral nodular enhancement
contiguous with the ablated HCC on dynamic imaging or an
enlarged ablated area on follow-up imaging of HCC that had
previously been completely ablated [6,8].
The primary end point of the study was overall survival;
the secondary endpoint was LTP.
Statistical analysis
The outcomes were compared between the tumor size
(2.0e3.0 cm vs. 3.1e4.0 cm) and tumor location subgroups
(non-high-risk location vs. high-risk location). Baseline
characteristics and outcomes between subgroups were
analyzed with a c2 test or Fisher’s exact test for categorical
data and the ManneWhitney U test for continuous data.
Cumulative survival and LTP were analyzed with the
KaplaneMeier method and the difference was determined
by the log-rank test. Univariate analyses were performed
using the Cox regression model to identify possible risk
factors for death and LTP. A p value <0.05 was considered
statistically significant.
Results
The baseline characteristics are shown in Table 1. Initially,
79 patients with 101 HCCs underwent combination therapy
during the study period. Twenty-five patients were
excluded from the study, including 23 patients with trans-
arterial chemoembolization prior to combination treat-
ment, one foreign patient, and one patient with massive
ascites without imaging follow up after RFA. Twelve pa-
tients had more than one HCC. Complete ablation and
primary technique effectiveness were analyzed according
to 72 HCCs with tumor-based data (Table 1), and long-term
outcomes were analyzed in 54 patients (Table 2).
Complete ablation and primary technique
effectiveness
Complete ablation after one session of treatment was ach-
ieved in 66 of 72 HCCs (91.7%). The other six HCCs were all
located in high-risk locations. Specifically, two tumors were
near vessels (middle and right hepatic veins); two tumors
were near the biliary tract; one tumor was near the dia-
phragm; and one tumor was near a kidney. Four of the six
tumors were completely ablated after the second session of
treatment. The two tumors located near the middle hepatic
vein and kidney did not achieve PTE. The PTE ratewas 97.2%.LTP
Eighteen HCCs developed LTP (25%) during follow-up (me-
dian, 31.5  23.6 months; range, 1.8e92.0 months), and
LTP developed in 13 of 50 (26%) HCCs 2e3 cm in size, and
five of 22 (22.7%) HCCs 3.1e4.0 cm in size (p Z 0.768). In
the 2e3-cm tumor group, five of 15 tumors (33.3%) near
vessels and four of 26 (15.4%) tumors near vital structures
developed LTP (pZ 0.248). Four of 12 (33.3%) HCCs in non-
high-risk locations and 14 of 60 (23.3%) HCCs in high-risk
locations developed LTP (p Z 0.479). Six of 19 (31.6%) tu-
mors near vessels and eight of 41 (22.9%) tumors near vital
structures developed LTP (p Z 0.338; Table 3). Tumors
located near vessels received more RFA sessions and higher
ethanol volume, but had lower complete ablation and PTE,
and higher LTP.
The cumulative LTP rate at 1 year, 2 years, and 3 years
for all index tumors was 10.2%, 28.2%, and 32.6%, respec-
tively; 12.6%, 30.6%, and 33.9% in tumors 2.0e3.0 cm in
size; 4.8%, 23.1%, and 29.5% in tumors 3.1e4.0 cm in size
(p Z 0.616); 16.7%, 33.3%, and 50% in tumors in non-high-
risk locations; and 8.8%, 27.3%, and 29.9% in tumors in
high-risk locations (p Z 0.283). Univariate analysis showed
that only tumor differentiation was a significant factor
related to LTP (p Z 0.02).
New HCC recurrence
During the follow-up period (48.0  24.6 months; median,
54.3 months), 39 of 54 (73%) patients had new HCC recur-
rence. There were no apparent risk factors for the new
Table 2 Comparison of baseline characteristics and treatment responses in 72 HCCs with different sizes and locations.
Variables Size p Location p
2.0e3.0 cm 3.1e4.0 cm Non-high-risk High-risk
Baseline characteristics
Tumor no. 50 (69.4) 22 (30.6) 12 (16.7) 60 (83.3)
Size (cm) 2.4  0.3 3.5  0.3 <0.001 2.7  0.6 2.8  0.6 0.886
ChildePugh A 41 (82) 20 (90.9) 0.485 11 (91.7) 50 (83.3) 0.677
Near vessel 15 (30.0) 4 (18.1) 0.390 0 19 (31.7)
Near vital structurea 26 (52.0) 15 (68.2) 0.201 0 41 (68.3)
Ablation time (min) 19.7  10.9 26.1  14.2 0.035 21.7  9.4 21.7  12.8 0.629
Ethanol use (mL) 4.0  1.3 4.4  1.9 0.376 3.8  1.1 4.2  1.6 0.358
No. of electrode repositions 1.8  0.9 2.1  1.1 0.295 2.0  0.9 1.9  1.0 0.737
Treatment response
Complete ablation 46 (92.0) 20 (90.9) 1.000 12 (100.0) 54 (90.0) 0.581
Primary technique effectiveness 49 (98.0) 21 (95.5) 0.521 12 (100.0) 58 (96.7) 1.000
Local tumor progression 13 (26.0) 5 (22.7) 0.768 4 (33.3) 14 (23.3) 0.479
Data are presented as n (%) or mean  SD.
HCC Z hepatocellular carcinoma.
a Vital structure in this table excludes blood vessels.
Table 3 Therapeutic details in 72 HCCs at different locations.
Definite location No. of
tumors











12 2.71  0.63 3.75  1.14 2  0.85 21.67  9.41 12 (100) 12 (100) 4 (33.3)
Vessel 19 2.71  0.62 4.69  2.08 1.79  0.98 23.84  16.67 17 (89.4) 18 (94.7) 6 (31.6)
Diaphragm 19 2.67  0.59 3.87  1.42 1.74  0.73 18.61  6.87 18 (94.7) 19 (100) 6 (31.6)
Biliary tree 15 2.92  0.53 4.07  1.28 2.13  0.92 23.53  11.99 13 (86.7) 15 (100) 2 (13.3)
GI tract and others 7 2.69  0.38 4.07  1.24 2.14  1.46 20.14  15.75 6 (85.7) 6 (85.7) 0 (0)
Data are presented as n (%) or mean  SD.
HCC Z hepatocellular carcinoma; LTP Z local tumor progression; PTE Z primary technique effectiveness; RFA Z radiofrequency
ablation.
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tients with liver cirrhosis (p Z 0.084, odds ratio Z 4.36,
95% confidence interval 0.84e22.54) tended to have more
new recurrences.
Overall survival
During follow-up, 16 of 54 (29.6%) patients died, 18 (16 lost
to follow-up and 2 received liver transplantation) of 54
(33.3%) patients withdrew, and 20 of 54 (37.0%) patients
were alive. The deaths were largely due to liver failure
(75%) related to rapid liver decompensation with sepsis
caused by pneumonia (n Z 3), biliary tract infection
(n Z 2), spontaneous bacterial infection (n Z 4), post-
operative duodenal ulcer with bacteremia and fungemia
(n Z 1), and post-chemotherapy for HCC with neutropenia
and septic shock (n Z 1). One patient died of a hepatitis B
flare with liver failure. Another cause of death was variceal
bleeding (n Z 2), HCC rupture (n Z 1), and tumor pro-
gression and transfer to hospice care (n Z 1). The mean
survival was 33.7  23.5 months (median, 31.6 months;
range, 4.4e94.6 months). Twenty-one of 32 (65.6%) pa-
tients with tumors 2e3 cm in size and 17 of 22 (77.2%)patients with tumors 3.1e4 cm in size remained alive at
analysis. The cumulative survival rate at 1 year, 3 years,
and 5 years for all patients was 92.2%, 81.0%%, and 67.6%,
respectively; 90.3%, 78.9%, and 60.3% in the 2.0e3.0-cm
group; 95.0%, 84.4%, and 69.3% in the 3.1e4.0-cm group
(p Z 0.397); 90.0%, 71.1%, and 71.1% in non-high-risk lo-
cations; and 92.7%, 81.6%, and 65.4% in high-risk locations
(p Z 0.979). Univariate analysis, including tumor size and
tumor location, were not significant risk factors. Due to
disease progression after initial combination therapy, 22
patients received transarterial chemoembolization during
follow-up.
Adverse effects
The definitions of ablation-related complications and side
effects were according to the Standardization of Termi-
nology and Reporting Criteria [12]. One patient with an
index HCC under the diaphragm had an asymptomatic
pleural effusion. Among all of the patients, there were 26
(36%) episodes of grade 1 or 2 abdominal pain and eight
(11.1%) episodes of low-grade fever after treatment; the
pain and fever were both controlled after medication.
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Previous studies have shown RFA alone can achieve a better
outcome in small HCCs (3 cm) [5]. Moreover, combining
PEI and RFA can achieve a better outcome in HCCs
3.1e5.0 cm in size and difficult-to-treat HCCs; especially
tumors close to large vessels or vital organs [10]. The
mechanisms favoring combination therapy probably include
the expansion of the ablation area by diffusion of hot
ethanol into the areas not reached by RF power and
reduction in the heat-sink effect [8,10,13]. The current
results confirm that combining RFA and PEI can achieve
comparable long-term outcomes in patients with larger
HCCs measuring 2e3 cm versus 3.1e4 cm and in high-risk
locations versus non-high-risk locations.
Previous studies [14], including meta-analyses [15,16],
have shown that 85e100% of HCCs  3e4 cm and 96e100%
of small HCCs (<3 cm) in size are completely ablated after
RFA. The current study showed a comparable complete
ablation rate compared with previous studies.
Previous studies have also shown that the LTP rate of
small HCCs after RFA was 1.3e14% at 1 year, 1.7e24% at
2 years, and 1.7e30% at 3 years [7,14,17e19], whereas the
corresponding rates were higher in our study. The subop-
timal results of LTP in our study may be related to the
limited sensitivity of detecting residual viable tumors after
RFA with dynamic CT scan [20] and the higher recurrence
rates after RFA for HCCs > 3 cm and located near intra-
hepatic blood vessels and in subcapsular locations [21]. In
addition, because 83.3% of patients with HCC in this series
were in high-risk locations, the LTP might be higher than
that reported elsewhere [7,17e19].
To determine the impact of tumor size on treatment
effects, no significant relationship was found between
subgroups. This finding implies that combining PEI and RFA
can induce a synergistic necrotizing effect and expand
coagulation volumes, which are larger than those obtained
with PEI or RFA alone. Indeed, Vallone et al. [9] reported
that combining PEI and RFA is effective in HCCs > 4.0 cm in
size.
Combining PEI and RFA can also achieve a better effect
for HCCs in high-risk locations by reducing the heat-sink
effect [22]. However, RFA for HCCs in high-risk locations
may result in more complications or inadequate safety
margins due to concern about complications. In our study
there was no difference in the complete ablation rate be-
tween HCCs in high-risk locations and non-high risk
locations.
Univariate analysis showed that tumor differentiation
influenced LTP after combination treatment. Tumors with
poor differentiation have a higher incidence of satellite
nodules and microvascular invasion, which may contribute
to higher LTP [23]. Our study also showed that combination
treatment might reduce the LTP in larger HCCs and HCCs in
high-risk locations. The benefit might be due to the
expansion of the ablation area, including the area con-
taining satellite nodules.
After RFA, the intrahepatic new recurrence rate of HCCs
was 13e36% at 1 year, 24e38% at 2 years, 30e49% at
3 years, and up to 81% at 4 years [14,17e19,24]. Newrecurrences in this study were slightly fewer than in a
previous study [3].
In our study no significant complications were noted.
Livraghi et al. [6] reported a 1.8% complication rate in
HCCs < 2.0 cm in size after RFA, which was comparable to
our results. This finding was due to the safety of combina-
tion treatment in the prevention of thermal injuries to
adjuvant vital structures.
Shiina et al. [25] reported 1-, 3-, and 5-year survival
rates of 96.6%, 80.5%, and 65.1% in a 10-year follow-up
study. Moreover, the study also showed that HCC 3 cm
in size was a favorable factor for survival. Compared to the
previous report, the 1-, 3-, and 5-year survival rates in our
series were slightly better at 3 years and 5 years, even in
our patients with relatively larger HCCs (median, 2.63 cm;
mean, 2.74  0.57 cm), and more patients had HCCs in
high-risk locations. Previous studies have shown that sig-
nificant factors for longer survival were as follows: smaller
tumors (2 or 3 cm); Barcelona Clinic Liver Cancer (BCLC)
stage A; higher albumin level (3.5 gm/dL); higher platelet
count (100,000/mm3); lower serum lectin-reactive a-
fetoprotein level (10%); [26] and complete ablation at
1 month [19]. Our study showed that the addition of PEI was
the only important factor related to better survival, which
might have been due to the effects of combination therapy
or smaller sample size.
The satisfactory survival rate in our study may be
attributed to better local control after combination ther-
apy. Therefore, with the exception of the two patients who
died (HCC rupture and chemotherapy with neutropenia and
sepsis), the major cause of death in our study was not
related to tumor progression, but due to underlying liver
disease or nonhepatic causes [HCC progression vs. non-
eHCCerelated causes (12.5% vs. 87.5%)]. Univariate anal-
ysis, including tumor size and location, revealed no
significant risk factors, which implies combination therapy
may overcome large size and high-risk location.
Some limitations were encountered in this study. First,
the sample size was small. Our study did show that com-
bination treatment could achieve a comparable effect be-
tween patients with larger HCCs and high-risk locations.
Second, long-term follow-up analysis was begun in 2004.
The novel RFA with multiple electrodes and switching the
RF controller have emerged in recent years, thus, the
benefit of combing PEI and RFA may not be clearly
demarcated.
In conclusion, our study showed that combining RFA and
PEI could achieve comparable long-term outcomes in sub-
groups of HCCs (2e3 cm vs. 3.1e4.0 cm or high-risk vs. non-
high-risk locations). We may conclude that combining radio-
frequency ablation and ethanol injection may achieve com-
parable long-term outcomes in the larger HCC of 3.1e4 cm
compared with HCC <3.1 cm and in high-risk locations.
However, due to the absence of patients who received RFA
alone for comparison, ourfindings donotdefinitely prove that
combination therapy is superior toRFAaloneorother curative
treatment. Further randomized controlled trials or compar-
ative studies with a larger sample size might be required to
further confirm the benefit of combination treatment for
larger HCCs or HCCs in high-risk locations.
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